13 results on '"Hurt, Aeron C"'
Search Results
2. Influenza and COVID‐19: What does co‐existence mean?
- Author
-
Chotpitayasunondh, Tawee, Fischer, Thea Kølsen, Heraud, Jean‐Michel, Hurt, Aeron C., Monto, Arnold S., Osterhaus, Albert, Shu, Yuelong, and Tam, John S.
- Subjects
COVID-19 ,PANDEMICS ,MEDICAL personnel ,COVID-19 pandemic ,EMERGING infectious diseases ,INFLUENZA ,SARS-CoV-2 - Abstract
The COVID‐19 pandemic caused by the novel coronavirus SARS‐CoV‐2 continues to have a major impact on healthcare and social systems throughout the world. As the clinical and epidemiological features of COVID‐19 have many parallels with influenza, it is important to ensure optimal management of both respiratory diseases as we anticipate their continued co‐circulation. In particular, there is a need to ensure that effective surveillance and diagnostic capacities are in place to monitor these and other respiratory viruses, as this will underpin decisions on the appropriate clinical management of the respective diseases. As such, we propose a series of key recommendations for stakeholders, public health authorities, primary care physicians and surveillance bodies that will help mitigate the combined risks of concurrent influenza epidemics and the COVID‐19 pandemic. We advocate the judicious use of influenza vaccines and antivirals, particularly among groups at high risk of complications, with healthcare workers also considered a priority for vaccination. It is likely that the increased use of emerging technologies such as telemedicine and contact tracing will permanently change our approach to managing infectious disease. The use of these technologies, alongside existing pharmaceutical strategies, will ensure that we achieve a holistic approach to the global public health measures needed to deal with the combined threat of influenza and COVID‐19. Ensuring that this approach is optimal will be key as we move from a reactive pandemic response towards preparing for the long‐term management of the remarkable clinical burden associated with these respiratory pathogens. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Viral burden, inflammatory milieu and CD8+ T‐cell responses to influenza virus in a second‐generation thiazolide (RM‐5061) and oseltamivir combination therapy study.
- Author
-
Nüssing, Simone, Mifsud, Edin, Hensen, Luca, Koutsakos, Marios, Wang, Zhongfang, Kedzierski, Lukasz, Mercuri, Francesca, Rossignol, Jean‐Francois, Hurt, Aeron C., and Kedzierska, Katherine
- Subjects
INFLUENZA A virus ,VIRUS diseases ,INFLAMMATION ,INFLUENZA ,DRUG efficacy ,DRUG resistance ,ANTIVIRAL agents ,NILOTINIB - Abstract
Background: Influenza viruses cause significant morbidity and mortality, especially in young children, elderly, pregnant women and individuals with co‐morbidities. Patients with severe influenza disease are typically treated with one neuraminidase inhibitor, oseltamivir or zanamivir. These antivirals need to be taken early to be most effective and often lead to the emergence of drug resistance and/or decreased drug susceptibility. Combining oseltamivir with another antiviral with an alternative mode of action has the potential to improve clinical effectiveness and reduce drug resistance. Methods: In this study, we utilized a host‐targeting molecule RM‐5061, a second‐generation thiazolide, in combination with oseltamivir to determine whether these compounds could reduce viral burden and understand their effects on the immune response to influenza virus infection in mice, compared with either monotherapy or placebo. Results: The combination of RM‐5061 and OST administered for 5 days after influenza infection reduced viral burden at day 5 post‐infection, when compared to placebo and RM‐5061 monotherapy, but was not significantly different from oseltamivir monotherapy. The inflammatory cytokine milieu was also reduced in animals which received a combination therapy when compared to RM‐5061 and placebo‐treated animals. Antiviral treatment in all groups led to a reduction in CD8+ T‐cell responses in the BAL when compared to placebo. Conclusions: To our knowledge, this is the first time a combination of a host‐targeting compound, RM‐5061, and neuraminidase inhibitor, OST, has been tested in vivo. This antiviral combination was safe in mice and led to reduced inflammatory responses following viral infection when compared to untreated animals. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions.
- Author
-
Koszalka, Paulina, Farrukee, Rubaiyea, Mifsud, Edin, Vijaykrishna, Dhanasekaran, and Hurt, Aeron C.
- Subjects
INFLUENZA viruses ,INFLUENZA B virus ,AMINO acids ,AMINO acid residues - Abstract
Baloxavir marboxil is a novel endonuclease inhibitor licensed for treatment of otherwise healthy or high‐risk individuals infected with influenza. Viruses with reduced baloxavir susceptibility due to amino acid substitutions at residue 38 of the PA have been detected in some individuals following treatment. Here, we describe a genotypic pyrosequencing method that can be used to rapidly screen circulating influenza A and B viruses for substitutions in the PA/I38 codon and to quantify mixed viral populations. This method is suitable for surveillance of baloxavir susceptibility and to analyse samples from hospitalised patients undergoing baloxavir treatment to aid in clinical decision making. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Circulation and characterization of seasonal influenza viruses in Cambodia, 2012‐2015.
- Author
-
Horwood, Paul F., Karlsson, Erik A., Horm, Srey Viseth, Ly, Sovann, Heng, Seng, Chin, Savuth, Darapheak, Chau, Saunders, David, Chanthap, Lon, Rith, Sareth, Y, Phalla, Chea, Kim Lay, Sar, Borann, Parry, Amy, Ieng, Vanra, Tsuyouka, Reiko, Deng, Yi‐Mo, Hurt, Aeron C., Barr, Ian G., and Komadina, Naomi
- Subjects
SEASONAL influenza ,INFLUENZA viruses ,INFLUENZA A virus ,INFLUENZA A virus, H1N1 subtype ,MEDICAL sciences ,INFLUENZA B virus ,INFLUENZA ,ANTIVIRAL agents - Abstract
Background: Influenza virus circulation is monitored through the Cambodian influenza‐like illness (ILI) sentinel surveillance system and isolates are characterized by the National Influenza Centre (NIC). Seasonal influenza circulation has previously been characterized by year‐round activity and a peak during the rainy season (June‐November). Objectives: We documented the circulation of seasonal influenza in Cambodia for 2012‐2015 and investigated genetic, antigenic, and antiviral resistance characteristics of influenza isolates. Patients/Methods: Respiratory samples were collected from patients presenting with influenza‐like illness (ILI) at 11 hospitals throughout Cambodia. First‐line screening was conducted by the National Institute of Public Health and the Armed Forces Research Institute of Medical Sciences. Confirmation of testing and genetic, antigenic and antiviral resistance characterization was conducted by Institute Pasteur in Cambodia, the NIC. Additional virus characterization was conducted by the WHO Collaborating Centre for Reference and Research on Influenza (Melbourne, Australia). Results: Between 2012 and 2015, 1,238 influenza‐positive samples were submitted to the NIC. Influenza A(H3N2) (55.3%) was the dominant subtype, followed by influenza B (30.9%; predominantly B/Yamagata‐lineage) and A(H1N1)pdm09 (13.9%). Circulation of influenza viruses began earlier in 2014 and 2015 than previously described, coincident with the emergence of A(H3N2) clades 3C.2a and 3C.3a, respectively. There was high diversity in the antigenicity of A(H3N2) viruses, and to a smaller extent influenza B viruses, during this period, with some mismatches with the northern and southern hemisphere vaccine formulations. All isolates tested were susceptible to the influenza antiviral drugs oseltamivir and zanamivir. Conclusions: Seasonal and year‐round co‐circulation of multiple influenza types/subtypes were detected in Cambodia during 2012‐2015. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. Influenza antivirals currently in late-phase clinical trial.
- Author
-
Koszalka, Paulina, Tilmanis, Danielle, and Hurt, Aeron C.
- Subjects
OSELTAMIVIR ,ANTIVIRAL agents ,INFLUENZA treatment ,CLINICAL drug trials ,DRUG efficacy - Abstract
Influenza antiviral drugs are important for the control of influenza, most specifically for the treatment of influenza patients with severe disease following infection with a seasonal influenza virus, a newly emerging influenza strain, or in the event of a pandemic. Many influenza antivirals that are currently under investigation in late-stage clinical trials differ in their mechanism of action compared to drugs currently licensed for the treatment of influenza. Nitazoxanide and DAS181 target components of the host cell and alter the ability of the virus to replicate efficiently, while small molecule drugs such as T705, JNJ63623872 and S-033188 bind to the viral polymerase complex and restrict viral replication. Monoclonal antibodies that are currently in clinical trial for the treatment of influenza most commonly are targeted to the stem region of the haemagglutinin molecule. Early findings from animal models and in vitro studies suggest that many of the new antiviral drugs when tested in combination with oseltamivir have improved effectiveness over monotherapy. Clinical trials assessing both monotherapy and combination therapy are currently under investigation. It is hoped that as new antivirals are licensed, they will improve the standard of care and outcomes for influenza patients with severe disease. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Overview of the 3rd isirv-Antiviral Group Conference - advances in clinical management.
- Author
-
Hurt, Aeron C., Hui, David S., Hay, Alan, and Hayden, Frederick G.
- Subjects
- *
ANTIVIRAL agents , *IMMUNOCOMPROMISED patients , *INFLUENZA , *RHINOVIRUSES , *RESPIRATORY syncytial virus - Abstract
This review highlights the main points which emerged from the presentations and discussions at the 3rd isirv- Antiviral Group Conference - advances in clinical management. The conference covered emerging and potentially pandemic influenza viruses and discussed novel/pre-licensure therapeutics and currently approved antivirals and vaccines for the control of influenza. Current data on approved and novel treatments for non-influenza respiratory viruses such as MERS- Co V, respiratory syncytial virus ( RSV) and rhinoviruses and the challenges of treating immunocompromised patients with respiratory infections was highlighted. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Peramivir and laninamivir susceptibility of circulating influenza A and B viruses.
- Author
-
Leang, Sook‐Kwan, Kwok, Simon, Sullivan, Sheena G., Maurer‐Stroh, Sebastian, Kelso, Anne, Barr, Ian G., and Hurt, Aeron C.
- Subjects
RELENZA (Drug) ,INFLUENZA A virus ,INFLUENZA B virus ,DISEASE susceptibility ,NEURAMINIDASE ,GENETIC mutation ,THERAPEUTICS - Abstract
Influenza viruses collected from regions of Asia, Africa and Oceania between 2009 and 2012 were tested for their susceptibility to two new neuraminidase inhibitors, peramivir and laninamivir. All viruses tested had normal laninamivir inhibition. However, 3·2% (19/599) of A(H1N1)pdm09 viruses had highly reduced peramivir inhibition (due to H275Y NA mutation) and <1% (6/1238) of influenza B viruses had reduced or highly reduced peramivir inhibition, with single occurrence of variants containing I221T, A245T, K360E, A395E, D432G and a combined G145R+Y142H mutation. These data demonstrate that despite an increase in H275Y variants in 2011, there was no marked change in the frequency of peramivir- or laninamivir-resistant variants following the market release of the drugs in Japan in 2010. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Second isirv antiviral group conference: overview.
- Author
-
Hurt, Aeron C., Ison, Michael G., Hayden, Frederick G., and Hay, Alan J.
- Subjects
- *
ANTIVIRAL agents , *CONFERENCES & conventions , *EPIDEMIOLOGY , *RESPIRATORY infections , *VIRUS diseases , *INFLUENZA treatment , *CRITICAL care medicine - Published
- 2013
- Full Text
- View/download PDF
10. Progressive emergence of an oseltamivir-resistant A( H3 N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient.
- Author
-
Hurt, Aeron C., Leang, Sook Kwan, Tiedemann, Karin, Butler, Jeff, Mechinaud, Francoise, Kelso, Anne, Downie, Peter, and Barr, Ian G.
- Subjects
- *
INFLUENZA treatment , *OSELTAMIVIR , *DRUG resistance , *IMMUNOCOMPROMISED patients , *JUVENILE diseases , *ANTIVIRAL agents , *GENETIC mutation - Abstract
A minor viral population of oseltamivir-resistant A( H3 N2) viruses ( E119 V neuraminidase mutation) was selected and maintained in a continually infected immunocompromised child following initial oseltamivir treatment. A subsequent course of oseltamivir given 7 weeks later rapidly selected for the E119 V variant resulting in a near-pure population of the resistant virus. The study highlights the challenges of oseltamivir treatment of immunocompromised patients that are continually shedding virus and demonstrates the ability of the E119 V oseltamivir-resistant virus to be maintained for prolonged periods even in the absence of drug-selective pressure. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
11. The significance of increased influenza notifications during spring and summer of 2010-11 in Australia.
- Author
-
Kelly, Heath A., Grant, Kristina A., Tay, Ee Laine, Franklin, Lucinda, and Hurt, Aeron C.
- Subjects
RESPIRATORY infections ,INFLUENZA diagnosis ,BLOOD agglutination ,SEASONAL variations of diseases ,CLINICAL pathology - Abstract
Please cite this paper as: Kelly et al. (2012) The significance of increased influenza notifications during spring and summer of 2010-11 in Australia. Influenza and Other Respiratory Viruses. DOI: 10.1111/irv.12057. Background & objective During the temperate out-of-season months in Australia in late 2010 and early 2011, an unprecedented high number of influenza notifications were recorded. We aimed to assess the significance of these notifications. Methods For Australia, we used laboratory-confirmed cases notified to the WHO FluNet surveillance tool; the percentage of these that were positive; notifications by state and influenza type and subtype; and surveillance data from Google FluTrends. For the state of Victoria, we used laboratory-confirmed notified cases and influenza-like illness (ILI) proportions. We compared virus characterisation using haemagglutination-inhibition assays and phylogenetic analysis of the haemagglutinin gene for seasonal and out-of-season notifications. Results The increase in notifications was most marked in tropical and subtropical Australia, but the number of out-of-season notifications in temperate Victoria was more than five times higher than the average of the previous three seasons. However, ILI proportions in spring-summer were not different to previous years. All out-of-season viruses tested were antigenically and genetically similar to those tested during either the 2010 or 2011 influenza seasons. An increase in the number of laboratories testing for influenza has led to an increase in the number of tests performed and cases notified. Conclusion An increase in influenza infections in spring-summer of 2010-11 in tropical and temperate Australia was not associated with any differences in virus characterisation compared with viruses that circulated in the preceding and following winters. This increase probably reflected a natural variation in out-of-season virus circulation, which was amplified by increased laboratory testing. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. Performance of influenza rapid point-of-care tests in the detection of swine lineage A(H1N1) influenza viruses.
- Author
-
Hurt, Aeron C., Baas, Chantal, Yi-Mo Deng, Roberts, Sally, Kelso, Anne, and Barr, Ian G.
- Subjects
- *
H1N1 influenza , *VIRUS diseases in swine , *IMMUNOASSAY , *ANTIGENS , *LINEAGE - Abstract
Background In April 2009, an A(H1N1) influenza virus of swine lineage was detected in humans in the USA, and in just over a month has infected over 10 000 people in more than 40 countries. Objectives To determine the performance of the Binax Now, BD Directigen EZ, and the Quidel QuickVue influenza rapid point-of-care (POC) tests for the detection of the recently emerged swine lineage A(H1N1) virus. Methods Swine lineage A(H1N1) and human seasonal influenza strains were cultured and then diluted to specific infectivity titres. Viral dilutions were assayed by the rapid POC tests and by real-time RT-PCR. Results All three of the rapid POC tests successfully detected the swine lineage A(H1N1) viruses at levels between 103 and 105 TCID50/ml (tissue culture infectious dose50), with the BD Directigen test demonstrating marginally greater sensitivity than the other two tests. Viral infectivity and RNA load data for viruses at the detection limit of the rapid test kits, suggested that both the Quidel and the Binax tests were less sensitive for the detection of swine lineage A(H1N1) viruses than for human seasonal strains. In comparison the BD Directigen demonstrated similar sensitivity when detecting swine lineage A(H1N1) and human seasonal viruses. Conclusions The three rapid POC tests all detected the emergent swine lineage A(H1N1) virus when it was present at high virus concentrations. Early diagnosis of infection can assist in the rapid treatment. However the tests are significantly less sensitive than PCR assays and as such, negative results should be verified by a laboratory test. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
13. Cover.
- Author
-
Nüssing, Simone, Mifsud, Edin, Hensen, Luca, Koutsakos, Marios, Wang, Zhongfang, Kedzierski, Lukasz, Mercuri, Francesca, Rossignol, Jean‐Francois, Hurt, Aeron C., and Kedzierska, Katherine
- Subjects
INFLUENZA A virus - Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.